Posted inGastroenterology news Specialties
Durable Remission and Safety of Upadacitinib in Moderate to Severe Ulcerative Colitis: Insights from the Phase 3 U-ACTIVATE Long-Term Extension Interim Analysis
Interim data from the U-ACTIVATE study demonstrate sustained clinical and endoscopic remission and a consistent safety profile for upadacitinib up to 3 years in moderate to severe ulcerative colitis.